Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Alcon’s Pazeo Solution for ocular allergy itch relief
The company said that Pazeo solution is dosed one drop daily, and was approved with efficacy data at 24 hours, post dose. The approval was based on data
The company said that Pazeo solution is dosed one drop daily, and was approved with efficacy data at 24 hours, post dose. The approval was based on data
Also known as anti-PDL1 and RG7446, MPDL3280A is an investigational monoclonal antibody, designed to interfere with a protein called PD-L1. The approval was granted to treat these patients
Glyxambi is approved as an adjunct to diet and exercise to improve glycemic control in these adults when both empagliflozin and linagliptin are appropriate treatments. The drug is
Factor VIIa-CTP is a new, long-acting recombinant Factor VIIa using the company’s proprietary technology to extend its circulatory half-life without the use of polymers, encapsulation techniques or nanoparticles.
Zohydro ER is developed to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BeadTek is designed to
Compared to other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatory drugs, Anatabine Citrate has a distinct anti-inflammatory mode of action. The three-part Phase I trial
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) designed for acute and long-term use in the management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as
SL-701 is designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that occur in both adults and children. Antitumor activity
The announcement also includes the study in Liberia sponsored by investigators at the University of Oxford and the supportive Phase II trial of brincidofovir for Ebola Virus Disease
Vyvanse is the first and only medication approved for sale in the US for the treatment of this disorder. The approval was based on results from two randomized,